Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Feb 03, 2020

PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference

SOUTH PLAINFIELD, N.J. , Feb. 3, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will host a conference call on Thursday, February 6, 2020 , at 8:00 am ET highlighting data on risdiplam in type 2/3 spinal muscular atrophy patients from part 2 of the

Feb 03, 2020

PTC Therapeutics Announces First Publication of Real-World Data Showing TranslarnaTM (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy

- STRIDE registry analysis shows Translarna preserved ambulation and physical function by years compared with those in CINRG Duchenne Natural History Study, with no new safety signals1- - Trend toward delayed worsening of pulmonary function compared with natural history study1- SOUTH PLAINFIELD,

Jan 23, 2020

Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy

- Study meets primary endpoint in patients living with type 1 SMA - - To date, more than 400 patients have been treated with risdiplam across all studies, with no treatment related safety findings leading to study withdrawal in any risdiplam trial - - Risdiplam PDUFA expected May 24, 2020 - SOUTH

Jan 13, 2020

PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference

- PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 - - 3 clinical trials from PTC's new redox platform to begin in 2020 - - ~ $306 million preliminary unaudited 2019 total revenue - - 2020 Duchenne franchise revenue guidance of $320-340 million - SOUTH PLAINFIELD, N.J. , Jan.

Jan 06, 2020

PTC Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J. , Jan. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 th at 8:30 a.m. PST .

Dec 13, 2019

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Dec. 13, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its common stock to 17 new employees.

Nov 29, 2019

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Nov. 29, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of 144,550 shares of its common stock to 36 new employees.

Nov 25, 2019

PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy

- PDUFA date set for May 24, 2020- - NDA filing is based on data in a broad SMA population of Type 1, 2 and 3 patients- - FDA filing triggers $15M milestone payment to PTC from Roche- SOUTH PLAINFIELD, N.J. , Nov. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc.

Nov 19, 2019

PTC Therapeutics to Present at the Evercore ISI 2nd Annual HealthCONx Conference

SOUTH PLAINFIELD, N.J. , Nov. 19, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will participate in a panel discussion titled, "Gene Therapy with Base Business – Extracting Value," at the 2 nd Annual Evercore ISI HealthCONx Conference on Tuesday,

Nov 18, 2019

PTC Therapeutics Launches A No-Cost Testing Program to Drive AADC Deficiency Patient Identification

- AADC deficiency patients are often misdiagnosed as having other neurological conditions such as cerebral palsy - SOUTH PLAINFIELD, N.J. , Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid

Pagination

First page
Previous page
…
Page 22
Page 23
Current page 24
Page 25
Page 26
…
Next page
Last page